Furthermore, in another study on nasopharyngeal carcinoma, genistein-induced dose-dependent G2/M phase arrest in CNE-2 cell line in doses 30 to 120 μM, where SERMs (ER antagonist fulvestrant, ERα-specific agonist propyl pyrazole triol (PPT), and ERβ-specific agonist diarylprepionitrile (DPN)) did not affect genistein induced growth inhibition [137]. Here, ESR1 is linked to nasopharyngeal carcinoma.